SAB Bio’s SAFEGUARD Trial Progress and T1D Expansion Strategy Highlighted at Citi Summit

SAB Biotherapeutics (SABS) presented its clinical progress and strategic ambitions at Citi’s Biopharma Back to School Summit in September 2026, underscoring advancements in its lead candidate, SAB-142, for Type 1 diabetes (T1D). The company, with $208 million in cash reserves and a market cap of $314 million, projects a cash runway through 2028, supported by a current ratio of 9.2. Its focus remains on the SAFEGUARD trial, with over 60 clinical sites activated and full enrollment targeting Q4 2026. Top-line data is expected in the second half of 2027, while the trial spans pediatric and adult patients aged 5 to 40, with a primary endpoint of C-peptide preservation at 48 weeks. Secondary metrics include HbA1c reduction, insulin dependency, and hypoglycemia frequency, measured via continuous glucose monitors. The dosing regimen—two-day infusions every six months—distinguishes SAB-142 from competitors like Sanofi’s TZIeld, which requires a 12-day course annually at a cost of $356,000 per year. SAB-142’s platform leverages genetically engineered Transchromosomic cows to produce fully human intravenous immunoglobulin (IVIg) without serum sickness risks, enabling chronic dosing and redosing. The company is investing in a second facility in South Dakota to enhance plasma stockpile stability for up to a decade. A successful PRIZE trial expansion could initially double the addressable U.S. patient pool from 64,000 to 128,000, reflecting a conservative $4 billion market opportunity for SAFEGUARD-eligible patients alone. The company aims to launch with a field sales force of about 50 representatives targeting academic centers and key opinion leaders. Executives emphasized the platform’s scalability and the potential to reduce reliance on insulin and continuous glucose monitoring (CGM) for early-diagnosis T1D patients, positioning SAB Bio as a next-generation leader in the T1D space, where comparable human IVIg businesses are valued at $20 billion.